Policy & Regulation
BlueRock Therapeutics receives Health Canada approval to start Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy
8 April 2021 -

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has received approval from Health Canada to start its 'Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease,' it was reported on Wednesday.

This is the first trial in Canada to assess pluripotent stem cell-derived dopaminergic neurons in subjects with Parkinson's disease. The company is enrolling 10 patients in the United States and Canada for the trial, with the Canadian trial site at University Health Network, a research and teaching hospital network located in Toronto, Ontario.

The Ph1 study's primary objective is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.

Login
Username:

Password:


Related Headlines